At UHN, we strive to deliver Compassionate Care & Caring. Learn more about the services and supports that are available to you throughout your journey.
Our UHN programs and services are among the most advanced in the world. We have grouped our physicians,
staff, services and resources into 10 medical programs to meet the needs of our patients and help us make
the most of our resources.
At the heart of everything we do at UHN are our Healthcare Professionals. Refer a patient to one of our 12 medical programs. Learn more about the resources and opportunities available for professional growth.
University Health Network has grown to be one of the largest research and teaching hospital networks in Canada - pioneers in improving the lives of patients. Our long history of health professions education at Toronto General, Toronto Western, Princess Margaret and Toronto Rehab hospitals has consistently advanced the science of education.
University Health Network is a health care and medical research organization in
Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international
source for discovery, education and patient care.
Being touched by illness affects us in different ways. Many people want to give back to the community
and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one
of our experts for an interview. It's also the place to find UHN media policies and catch up on our news stories, videos, media releases,
podcasts and more.
While treatment for acute lymphoblastic leukemia (ALL) continues to advance, about 40 per cent to 75 per cent of adult patients who receive treatment experience relapse. The prognosis for patients who relapse is poor. It is thought that while chemotherapies eliminate most leukemia cells, some resistant cells remain, and now researchers have narrowed in on why.
In a study recently published in
Cancer Discovery, Dr. John Dick, Senior Scientist at Princess Margaret Cancer Centre, in collaboration with partners at St. Jude's Research Hospital, were able to isolate distinct populations of ALL cells called subclones and identify them as diagnosis relapse initiating (dRI) clones.
Using advanced genomic analysis on the cells, the team revealed that dRI clones differ from other leukemia cells and are somehow resistant to therapies. They are also present at diagnosis, meaning there is opportunity to improve targeted treatment at the onset for improved outcomes later.
The research is a companion piece alongside a study published in
Blood Cancer Discovery in January. Together they describe the underlying properties of the clones that lead to ALL relapse.
"Our study has shown that genetic clones that contribute to disease recurrence already possess characteristics such as therapeutic tolerance that distinguish them from other clones at diagnosis," says Dr. Stephanie Dobson, first author of the study and member of Dr. Dick's Lab.
"Being able to isolate these clones at diagnosis, sometimes years prior to disease recurrence, has enabled us to begin to profile the properties allowing these particular cells to survive and act as reservoirs for relapse.
"This knowledge can be used to enhance our therapeutic approaches for targeting relapse and relapse-fated cells."
"Xenografting added considerable new insight into the evolutionary fates and patterns of subclones obtained from diagnosis samples," says Dr. Dick, who is also leader of the Ontario Institute for Cancer Research's (OICR) Acute Leukemia Translational Research Initiative and professor of molecular genetics at the University of Toronto.
"We were able to gather extensive information about the genetics of the subclones from our models, which helped us describe the trajectories of each subclone and the order in which they acquired mutations."
These findings open the door for future treatment options that could prevent the rate of relapse for patients with ALL.
The study was co-authored by Dr. Dick and Dr. Charles Mullighan of the St. Jude Department of Pathology.
This story has been adapted from the
St. Jude Children's Research Hospital news release and